Characterization of Fasiglifam-Related Liver Toxicity in Dogs

Akifumi Kogame,1 Yuu Moriya, Ikuo Mori, Liping Pan, Akio Morohashi,2 Takuya Ebihara,1 Hideo Fukui,1 Yoshihiko Tagawa,1 and Leslie Z. Benet

Drug Metabolism and Pharmacokinetics Research Laboratories (A.K., Y.M., A.M., T.E., Y.T.) and Drug Safety Research Laboratories (I.M., H.F.), Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan; Takeda Development Center Americas, Inc., Deerfield, Illinois (L.P.); and Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, California (L.Z.B.)

Received November 2, 2018; accepted February 7, 2019

ABSTRACT

Fasiglifam, a potent and highly selective agonist of G protein-coupled receptor 40, was developed for the treatment of type 2 diabetes mellitus. However, phase III clinical programs were terminated owing to liver safety concerns. Fasiglifam-related liver toxicity was also observed in repeat-dose dog toxicology studies, characterized by granulomatous inflammation with crystal formation in the liver and/or bile ducts. These histopathological changes were not observed in rat toxicology studies. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of dog liver sections obtained from a repeat-dose toxicity study indicated that the crystalline material in the affected dog liver contained fasiglifam and fasiglifam glucuronide (fasiglifam-G). Nonclinical mechanistic studies indicated that after 14 days of repeated oral dosing with [14C]fasiglifam at 200 mg/kg per day to dogs, the concentrations of fasiglifam and fasiglifam-G in the bile exceeded the solubility limit of these compounds in the bile (approximately 3000 μg/ml). After single oral 2- and 200-mg/kg doses administered to rats and dogs, fasiglifam and fasiglifam-G concentrations in dog bile were 5- to 10-fold higher than those in rat bile for the same dose of fasiglifam, while the bile flow rate adjusted by body weight was 4- to 8-fold lower in dogs than in rats. High fasiglifam and fasiglifam-G concentrations in dog bile together with lower bile flow rate could cause crystal formation in dog bile, resulting in secondary granulomatous inflammation in the dog liver.

Introduction

Fasiglifam (TAK-875), a potent and highly selective agonist of G protein-coupled receptor 40, was developed for the treatment of type 2 diabetes mellitus (T2DM). G protein-coupled receptor 40 is highly expressed in pancreatic β cells, and its activation induces insulin secretion. The insulinotropic effect of fasiglifam is strictly glucose dependent (Tsujihata et al., 2011). Fasiglifam only enhanced insulin secretion in islet cells in the presence of high ambient glucose, which is essential for a desired safety profile for the treatment of T2DM in terms of hypoglycemia risk. In clinical studies, fasiglifam reduced blood glucose and glycated hemoglobin levels with a low risk of hypoglycemia. In T2DM patients (Kaku, 2013). However, the clinical development of fasiglifam was terminated in phase III clinical trials because of liver safety concerns (Kaku et al., 2015, 2016). From the fasiglifam clinical data focusing on liver safety findings, one definite Hy’s law case [alanine aminotransferase (ALT) or aspartate aminotransferase >3 × upper limit of normal] and total bilirubin >2 × upper limit of normal] and two near Hy’s law cases were identified in fasiglifam-treated patients (Marcinak et al., 2018). Fasiglifam-related liver toxicity was also observed in repeat-dose dog toxicity studies. Fasiglifam treatment in these studies resulted in liver toxicity characterized by elevation of plasma aspartate aminotransferase, ALT, alkaline phosphatase, and/or bilirubin. Associated histopathological changes were characterized as portal/periporal granulomatous inflammation with crystal formation (Supplemental Figs. 1 and 2). This toxicity was observed in a 4-week study at a dose of 1000 mg/kg per day. The toxicity measures were greater than those observed for a dose of 150 mg/kg per day in a 13-week study and for a dose of 80 mg/kg per day in a 39-week study, indicating that the toxicity was both dose and duration dependent (Supplemental Table 1). Although elevations of serum bilirubin and ALT were observed in repeat-dose rat studies (Wolenski et al., 2017), no histopathological changes indicative of liver injury were observed in any rat studies even at the lethal dose of 2000 mg/kg per day.

Our previous study indicated that disposition and metabolism of fasiglifam were similar between human and animals (Kogame et al., 2018). Fecal excretion was the primary elimination route for unchanged fasiglifam in all species. In addition, no human-specific metabolites were noted, and all metabolites found in human were also observed in the nonclinical animal toxicology studies, suggesting that the fasiglifam-related liver toxicity observed in humans and dogs might not have been caused by the production of specific metabolites. Moreover, since glucuronidation is the major fasiglifam metabolic elimination pathway, the glucuronide of fasiglifam [fasiglifam glucuronide (fasiglifam-G)]...
could be considered as a liver toxicity candidate metabolite in addition to unchanged fasiglifam.

Dog liver toxicity was observed before the phase III study. Therefore, we conducted the present study to support the clinical development of fasiglifam. We identified the composition of foreign body materials observed in dog liver obtained from the 39-week repeat-dose studies by using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI TOF MS) analysis. Furthermore, we used several in vitro and in vivo approaches to characterize the mechanism of fasiglifam-related dog liver toxicity. Nonclinical mechanistic studies included the following: 1) metabolic profiles of [14C]fasiglifam in the plasma and liver samples; 2) potential covalent binding of fasiglifam-G to plasma and liver proteins; 3) [14C]fasiglifam accumulation in the plasma and liver of dogs; 4) disposition and metabolism of [14C]-fasiglifam in rats and dogs; 5) hepatic transporter studies of fasiglifam and fasiglifam-G; 6) concentrations of total radioactivity, fasiglifam, and fasiglifam-G in bile after single or repeated dosing of [14C]fasiglifam; 7) bile flow rate and bile pH in rats and dogs in the presence of [14C]fasiglifam; and 8) in vitro solubility study of fasiglifam and fasiglifam-G. Based on these studies, we predicted fasiglifam and fasiglifam-G concentrations in human bile of T2DM patients receiving 50 mg dose to justify the phase III studies. The potential risk of hepatotoxicity in humans was assessed as discussed herein.

Materials and Methods

Chemicals and Biologicals

Fasiglifam ([(3S)-6-[[2,6-dimethyl-4-{3-[methylsulfonyl]propoxy}biphenyl-3-yl]methoxy]-2,3-di hy dro-1-benzofuran-3-yl]acetic acid hemihydrate) and 2',6'-dimethyl-4'-{3-[methylsulfonyl]propoxy}biphenyl-3-carboxylic acid were synthesized by Takeda Pharmaceutical Company Limited (Kanagawa, Japan). Furthermore, [(3S)-6-[[2,6-dimethyl-4-{3-[methylsulfonyl]propoxy}biphenyl-3-yl]14C]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid hemihydrate ([14C]fasiglifam) and glucuronic acid conjugate of [14C]fasiglifam ([14C]fasiglifam-G) were synthesized by Daiichi Pure Chemicals Co., Ltd. (Tokyo, Japan) and Quotient Bioresearch (Pharmanon UK Limited, Cardiff, UK), respectively. Dog bile was purchased from Kitayama Labes Co. Ltd. (Yamaguchi, Japan). Human bile was purchased from KAC Co., Ltd. (Kyoto, Japan) and Wako Pure Chemical Industries, Ltd. (Osaka, Japan). [3H]Estradiol 17β-glucuronide (E217βG) and [3H]taurocholic acid (TCA) were purchased from PerkinElmer, Inc. (Waltham, MA). [3H]Pravastatin sodium salt was obtained from American Radiolabeled Chemicals (St. Louis, MO). Unlabeled pravastatin sodium salt and cyclosporin A were purchased from Wako Pure Chemical Industries, Ltd. Membrane vesicles were purchased from GenoMembrane Co., Ltd. (Kanagawa, Japan). The products were prepared from purified plasma membrane isolated from Sf9 cells infected with baculovirus-expressing rat and dog multidrug resistance-associated protein 2 (Mdr2) or bile salt export pump (Bsep). Rat and dog cryopreserved hepatocytes were purchased from Life Technologies Corporation (Carlsbad, CA).

Animals

Eight-week-old male Sprague-Dawley rats weighing 251–282 g were purchased from Charles River Laboratories Japan, Inc., (Ibaraki, Japan). Male beagle dogs (7–11 months old, 8.41–11.2 kg) were purchased from Kitayama Labes Co., Ltd. They were fed laboratory chow [for rats: CR-LPF (Oriental Yeast Co., Ltd., Tokyo, Japan); for dogs: CD-5M (CLEA Japan, Inc., Tokyo, Japan) or Labo D Stock (Nason Corporation, Yokohama, Japan)]. They had free access to water, and were housed in temperature- and humidity-controlled rooms (18–28°C; 38%–82%), with 12-hour light/dark cycles, for more than 1 week before use. All experiments involving animals were reviewed and approved by the Animal Care and Use Committee of Takeda Pharmaceutical Company Limited.

MALDI TOF MS

The composition of the foreign body material in the liver in the dog toxicity studies was determined by conducting direct mass spectrometric measurement of fresh-frozen sections of liver tissue containing the foreign body materials obtained from a dog showing hepatotoxicity in the 39-week oral toxicity study of fasiglifam at 150 mg/kg per day with a 13-week recovery period. Sections were cut at a thickness of 10 μm with a cryostat microtome (CM1950; Leica Microsystems, Germany). The sections were placed onto conductive slide glasses (indium tin oxide–coated slide glass) and stored at −80°C until MALDI TOF MS analysis. The tissue slices were equilibrated to room temperature for at least 20 minutes before analysis. The glass slides were placed onto a special AXIMA MS plate (Shimadzu Corporation, Kyoto, Japan) for tissue analysis and then immobilized using double-sided conductive tapes. Furthermore, 200 nl of peptide solution (10 nmol/ml angiotensin II in 0.1% trifluoroacetic acid and 10 nmol/ml adrenocorticotropic hormone 18-39 in 0.1% trifluoroacetic acid) was spotted for external calibration by manually pipetting near the tissue slices, and then 200 nl of matrix solution (20 mg/ml 2.5-dihydroxybenzoic acid in 50% acetonitrile/0.1% trifluoroacetic acid for positive mode or 4 mg/ml 9-aminocinacide in 70% methanol for negative mode) was manually spotted at the same position.

The tiny foreign body materials in the liver tissue slices were directly measured by microdispensing a trace amount of the matrix solutions onto the lesion sites containing the foreign body materials in the tissue slices. First, the location of the foreign body materials was observed by microscopy, and then a landmark was prepared in the proximity of that location on the tissue slices by using a needle or pen. The sample plates, on which glass slides were immobilized with double-sided conductive tape, were set on the stage part of a chemical printer, and then an image of the sample plate was acquired using a scanner attached to a chemical printer instrument. The print positions to microdispense the matrix solution onto tissue sections were determined based on the landmark on the obtained image. Three hundred picoliters of 20 mg/ml 2.5-dihydroxybenzoic acid in 50% acetonitrile/0.1% trifluoroacetic acid or 4 mg/ml 9-aminocinacide solution in 70% methanol were microdispensed onto the tissue sections at a total volume of 18 nl on a single spot.

Matrix solution was microdispensed onto spots on each tissue slice (marked as s1, s2, and s4 in Fig. 1) as the matrix toward the foreign body materials. After matrix deposition, each matrix deposit on the tissue slices was observed by microscopy. The matrix deposit, including foreign body materials, was measured by analyzing the foreign bodies (these spots are indicated by the red letters with numbers in Fig. 1). The printed positions corresponding to the normal region are shown by black letters with numbers in Fig. 1.

Direct measurement was performed on the tissue slices by using MALDI-TOF MS. The text file of the print positional information was exported from the chemical printer, and then direct analysis of the printed positions was performed based on the X and Y coordinates from the text file. The peptide solution, which was manually pipetted onto the glass slides, was used as an external calibration. Furthermore, tandem mass spectrometry (MS/MS) experiments were performed for the significant ions observed in the foreign body materials. The parameters for collision-induced dissociation were optimized to effectively produce fragment ions.

Rat Studies

The metabolite profiling studies of fasiglifam were investigated in intact and bile duct–cannulated (BDC) male rats. After a single oral administration of [14C]fasiglifam (final specific activity: 4.19 MBq/mg) at 2 and 200 mg/kg to the intact rats, blood and liver were collected at 1 hour (time to maximum concentration of fasiglifam in rats) (Negoro et al., 2010) and 8 hours after administration. The blood was collected from the abdominal aorta under anesthesia by using diethyl ether. The blood was immediately cooled under ice-chilled conditions, and the plasma was obtained by centrifugation at 8000g at 4°C. Subsequently, the total radioactivity in the plasma was measured. The residual plasma samples were used for the metabolite profiling study.

For the BDC rat study, the rats were cannulated under anesthesia with isoflurane. After the efflux of bile was confirmed, the [14C]fasiglifam formulation was administered into the duodenum of the rats at 2 and 200 mg/kg (final specific activity: 0.763 MBq/mg for 2 mg/kg and 0.00741 MBq/mg for 200 mg/kg). After administration, the rats were housed in Bollman cages. Bile was collected at 1-hour intervals for 8 hours, and then 8–24 hours under dry ice–chilled conditions. The total radioactivity in the bile was measured. The residual
bile samples in each period were mixed together with the obtained weight ratio and used for the metabolite profiling study. The pH of the bile was measured using pH test paper (MACHEREY-NAGEL; Düren, Germany).

Dog Studies

The blood, liver, and bile samples were collected at 2 hours (time to maximum concentration of fasiglifam in dogs) (Negoro et al., 2010) and 8 hours after single oral doses of 2 and 200 mg/kg (final specific activity: 4.01 MBq/mg for 2 mg/kg and 4.19 MBq/mg for 200 mg/kg) or 14-day repeated oral doses (final specific activity: 0.215 kBq/mg) of [14C]fasiglifam at 200 mg/kg to intact dogs. The dogs were anesthetized with thiopental or sodium pentobarbital at an intravenous dose of 25 mg/kg for the collection of the liver and bile. During the repeated-dosing study, the blood was collected at 5, 15, and 30 minutes and 1, 2, 4, 8, and 24 hours after the first, seventh, and 14th administrations. The blood was collected from the cephalic vein. Blood samples were immediately cooled under ice-chilled conditions, and plasma was obtained by centrifugation at approximately 10,000g at 4°C. Subsequently, total radioactivity in the plasma was measured. The gallbladder and liver were excised and immediately stored under ice-chilled conditions. Blood samples were collected from the cephalic vein at 5, 15, and 30 minutes and 1, 2, 4, 8, and 24 hours after the first, seventh, 13th, and 14th administrations. The blood was collected from the cephalic vein. Blood samples were immediately cooled under ice-chilled conditions, and plasma was obtained by centrifugation at approximately 10,000g at 4°C. Subsequently, total radioactivity in the plasma was measured. The blood, liver, and bile samples were collected at 2 hours (time to maximum concentration of fasiglifam in dogs) (Negoro et al., 2010) and 8 hours after single oral doses of 2 and 200 mg/kg (final specific activity: 4.01 MBq/mg for 2 mg/kg and 4.19 MBq/mg for 200 mg/kg) or 14-day repeated oral doses (final specific activity: 0.215 kBq/mg) of [14C]fasiglifam at 200 mg/kg to intact dogs. The dogs were anesthetized with thiopental or sodium pentobarbital at an intravenous dose of 25 mg/kg for the collection of the liver and bile. During the repeated-dosing study, the blood was collected at 5, 15, and 30 minutes and 1, 2, 4, 8, and 24 hours after the first, seventh, 13th, and 14th administrations. The blood was collected from the cephalic vein.

Fig. 1. Optical images of the matrix-deposited region on fresh-frozen liver tissues. Letters in black: spots on the normal region; letters in red: spots on the foreign body material.
Inhibitory Effects of Fasiglifam and Fasiglifam-G on Hepatobiliary Transporters. Transport studies were performed using the rapid filtration technique (van Staden et al., 2012). Briefly, 40 μl of transport medium [50 mmol/l 3-morpholinopropanesulfonic acid-Tris, 70 mmol/l KCl, and 7.5 mmol/l MgCl₂ (pH 7.0)] was added to Mrp2 or 10 mmol/l HEPES-Tris, 100 mmol/l KNO₃, 10 mmol/l Mg(NO₃)₂, and 50 mmol/l sucrose (pH 7.4) for Bsep containing radiolabeled compounds ([3H]E217G for Mrp2 and [3H]HTCA for Bsep) was preincubated at 37°C for 5 minutes. The reaction was initiated by the addition of 10 μl of membrane vesicle suspension (50 μg of protein) into the preincubated transport medium. The reaction mixture contained 5 mmol/l of ATP or AMP. The transport reaction was terminated by addition of 1 ml of ice-cold buffer [40 mmol/l 3-morpholinopropanesulfonic acid-Tris and 70 mmol/l KCl (pH 7.0) for Mrp2, or 10 mmol/l HEPES-Tris, 100 mmol/l KNO₃, and 50 mmol/l sucrose (pH 7.4) for Bsep] containing radiolabeled compounds ([3H]E217G for Mrp2 and [3H]HTCA for Bsep). The radioactivity retained on the filter was determined using the LSC.

Radioactivity in the plasma, bile, in vitro biologic samples, and organic solvent extracts was measured directly using the LSC [LSC-5100 (Aloka Co., Ltd., Tokyo, Japan); Tri-Carb 2100TR, 2700TR, 2900TR, 3100TR, or 3110TR (PerkinElmer Inc.); or LS 6000IC or 6500 (Beckman Coulter, Inc., Brea, CA)] with Hionic-Fluor (PerkinElmer Inc.) and liquid scintillator A (toluene-based scintillator; Wako Pure Chemical Industries Ltd.). Radioactivity in the liver homogenate was measured using the combustion method by employing a sample oxidizer (model 307 or A030701; PerkinElmer Inc.). Resultant [14C]CO₂ was trapped in the background value for offline and online detection, respectively. The crystal formation is likely to be driven by the biliary excretion ratio (ER) and the total plasma clearance (CLtot) values of fasiglifam (CLb = ER × CLtot).}

Data Analysis

Data are expressed as mean or mean ± S.D. values of the results from two to four animals. Values for Cmax_plasma and tmax_plasma of fasiglifam and fasiglifam-G (time to maximum concentration) were directly noted from the data. The terminal half-life and area under the plasma versus time-concentration curve were calculated from the measured values by using the noncompartmental model in WinNonlin (version 4.1; Pharsight Corporation, Mountain View, CA).

MALDI TOF MS

Direct mass spectrometric measurements were conducted for lesion sites containing the foreign body material in the liver sections from a dog in a 39-week oral gavage toxicity study of fasiglifam. The ions that corresponded to fasiglifam and fasiglifam-G were detected in the lesions containing the foreign body material (Supplemental Fig. 3), whereas the corresponding peaks were not observed in normal regions (Supplemental Fig. 4). The MS/MS experiment was performed at m/z 563.2 and 739.2 as precursor ions. Therefore, the ion at m/z 563.2 was identified to be potassiumated fasiglifam by comparing it with the MS/MS spectrum of the reference standard of fasiglifam (Supplemental Fig. 5). The ion at m/z 739.2 was estimated to be fasiglifam-G because a typical neutral loss of 176 Da was observed in the MS/MS spectrum (Supplemental Fig. 6). The predominant product ion in this MS/MS experiment also corresponded to the mass value of potassiumated fasiglifam (m/z 563.2). The relative intensities of the observed ions corresponding to both fasiglifam and their respective potassiumated forms were determined using the online radioisotope detector (model 505TR or 625TR; PerkinElmer Inc.) with Ultima-Flo AP (PerkinElmer Inc.) used as the liquid scintillator. The lower limit of quantitation was defined as twice and three times the background value for offline and online detection, respectively.

Quantification of Fasiglifam in Plasma

The concentrations of fasiglifam in plasma in the dog multiple dosing study were determined using HPLC. Forty-microliter aliquots of the plasma samples were mixed with 960 μl of the 5% ammonium solution. The mixed samples were heated to 98°C for 3 minutes and centrifuged at 2000 rpm for 15 minutes. The supernatant was injected into the Shimadzu LC-VP HPLC system (Shimadzu Corporation) equipped with an XBridge C18 column (4.6 mm i.d. × 150 mm, 5 μm; Waters Corporation) maintained at 40°C. The mobile phase consisted of 10 mmol/l ammonium formate (pH 3) : acetonitrile (9:11, v/v). A flow rate of 1 ml/min was maintained for the entire run. The eluted fasiglifam was monitored with absorbance at 235 nm. The lower limit of quantitation for fasiglifam was 0.2 μg/ml.

Solubility of Fasiglifam and Fasiglifam-G in Bile

The solubility of fasiglifam and fasiglifam-G in dog and human bile was assessed by measuring the recovery of radioactivity in the supernatant of the bile after centrifugation of the bile samples spiked with [14C]fasiglifam and [14C]fasiglifam-G at concentrations of 1, 3, and 10 mg/ml. The spiked samples were set in a water bath at 37°C for 60 minutes and centrifuged at approximately 1850g at 25°C for 10 minutes, and then the radioactivity in the supernatant was measured as the recovery of radioactivity.

Prediction Methods for Fasiglifam in Bile

The maximum concentration of fasiglifam in bile (Cmax_bile) was estimated using the maximum plasma concentration (Cmax_plasma) of fasiglifam, biliary clearance (CLb), and the bile flow rate (eq. 1):

\[ C_{\text{max\_bile}} = \frac{\text{CLb} \times C_{\text{max\_plasma}}}{\text{Bile flow rate}} \]
Evaluation of the Metabolic Profiles of [14C]Fasiglifam in the Plasma and Liver Samples

The concentrations of radioactivity in the plasma and liver were determined in rats and dogs treated with [14C]fasiglifam at single oral doses of 2 and 200 mg/kg. Following a single oral administration of the same dose, the concentrations of total radioactivity in the rat liver were 2- to 6-fold higher than those in the dog liver (Table 1). Metabolic profiling studies indicated that fasiglifam was the major component in the plasma (>85% of radioactivity) and liver (>57% of radioactivity) in rats and dogs. The concentrations of fasiglifam in the rat liver were 2-to 10-fold higher than those in the dog liver, while the concentrations of fasiglifam-G in the liver tended to be higher in dogs than in rats at the same oral dose (Fig. 2). The concentrations of fasiglifam-G were significantly lower than those of fasiglifam in the livers of rats and dogs.

Evaluation of the Potential Covalent Binding of Fasiglifam-G to Plasma and Liver Proteins

The potential covalent binding of fasiglifam-G (an acyl glucuronide) to the plasma and liver proteins was evaluated in rats and dogs treated with [14C]fasiglifam. Following a single oral and/or intravenous administration of [14C]fasiglifam to intact rats and dogs, the mean total recovery of radioactivity ranged from 95.9% to 99.3% (Kogame et al., 2018). These findings indicate that the administered [14C]fasiglifam was completely excreted in both species. No acyl migration of [14C]fasiglifam-G was detected in the plasma and liver of rats and dogs after oral administration of [14C]fasiglifam, and the total radioactivity in the plasma and liver of rats and dogs was extracted completely at an efficiency ranging from 91% to 109%. In addition, potential covalent binding of fasiglifam and its metabolites to the microsome samples was evaluated. In vitro cytochrome P450 and uridine diphosphate glucuronosyltransferase reaction phenotyping studies generated oxidative metabolites (2',6'-dimethyl-4'-[3-(methylsulfonyl)proproxy]biphenyl-3-carboxylic acid, T-1676427, and unidentified metabolites) and fasiglifam-G, respectively (Kogame et al., 2018). The recovery of the radioactivity through the pretreatment ranged from 98.4% to 104.9%.


Fourteen-day repeat-dose studies were conducted in male dogs at an oral [14C]fasiglifam dose of 200 mg/kg per day. The concentration-time profiles of total radioactivity and fasiglifam after the 14th administration were similar to those after the first, seventh, and 13th administrations of [14C]fasiglifam (Supplemental Fig. 7), suggesting that neither total radioactivity nor fasiglifam accumulated in the plasma during the 14-day dosing period.

In the liver, the concentrations of total radioactivity, fasiglifam, and fasiglifam-G at 2 and 8 hours postdose of the 14th administration were similar or slightly higher than those after the first administration (Supplemental Table 3), indicating that there was no appreciable accumulation of total radioactivity, fasiglifam, or fasiglifam-G in the liver after 14 days of repeated dosing.

Evaluation of the Disposition and Metabolism of [14C]Fasiglifam in Rats and Dogs

Disposition and metabolism of [14C]fasiglifam was evaluated in BDC male rats and in dogs following a single intraduodenal dose in rats and after oral administration to dogs. At a dose of 2 mg/kg, the mean total recovery concentrations of radioactivity at 24 hours postdose were 84.5% and 82.4% in rats and dogs, respectively; 81.4% and 78.2% of the dosed radioactivity were excreted into the bile of rats and dogs, respectively. These results showed that [14C]fasiglifam was well absorbed in rats and dogs at a dose of 2 mg/kg, and that the absorbed fasiglifam and related compounds were mainly excreted into the bile. At a dose of 200 mg/kg, the mean total recovery concentrations of radioactivity at 24 hours postdose were 84.4% and 54.7% in rats and dogs, respectively, with 54.1% and 42.0% of the dosed radioactivity being excreted into the bile for both, respectively. Data regarding excretion of total radioactivity are presented in Supplemental Table 4. A previous study showed that metabolism plays a greater role in the elimination of fasiglifam than biliary and urinary excretion of fasiglifam in both species, and glucuronidation of fasiglifam was the predominant metabolic pathway in both species (Kogame et al., 2018). The proposed metabolic pathways of fasiglifam are presented in Supplemental Fig. 8. Hence, fasiglifam-G was the main component in rat and dog bile (ranging from 41.6% to 78.8% of the total radioactivity), and metabolic profiles of bile samples were qualitatively similar between rats and dogs (Table 2). The biliary excretion of unchanged parent drug in dogs was similar to or slightly higher than that in rats (the adjusted biliary excretion ratios of fasiglifam were 13.8% and 7.0% of the dose in dogs and rats, respectively, at 2 mg/kg), whereas the amount of fasiglifam-tau formed in dogs was at least 3-fold lower than that in rats.

Hepatic Transporter Studies of Fasiglifam and Fasiglifam-G

The uptake of [14C]fasiglifam into hepatocytes was investigated in rats and dogs, and the results are summarized in Table 3. The hepatic uptake of [3H]pravastatin in hepatocytes was also investigated as a positive control for evaluating Oatp function. In the presence of cyclosporin A, the hepatic uptake CL of pravastatin was significantly reduced in rat and dog hepatocytes. These findings are consistent with reported data (Shitara et al., 2004; Wilby et al., 2011), suggesting that the rat and dog hepatocytes used in the present study retained Oatp function. The hepatic uptake CL values of [14C]fasiglifam were comparable between rats and dogs, indicating that no species difference existed in the hepatic uptake CL of [14C]fasiglifam. The uptake CL values of [14C]fasiglifam in rats and dogs were ≥43-fold higher than those of [3H]pravastatin, a substrate for Oatps. In addition, cyclosporin A, an inhibitor of Oatps and sodium taurocholate cotransporting polypeptide, had no or little inhibition (<20%) on the hepatic uptake CL of [14C]fasiglifam in rats and dogs. These findings suggest that
passive diffusion plays a more important role than transporter(s) in the hepatic uptake of \([^{14}C]\)fasiglifam in rats and dogs. The inhibitory effects of fasiglifam and fasiglifam-G on hepatobiliary transporters were evaluated, and the results are summarized in Table 4. No obvious species differences in potential inhibition were observed.

**TABLE 2**

Mean levels (percentages in parentheses) of fasiglifam and its metabolites in the bile of rats and dogs during 0–24 h following a single dose of \([^{14}C]\)fasiglifam

Each value represents an average of two animals. Numbers in parentheses represent proportions to the total radioactivity (%). The individual measurements are presented in Supplemental Table 5.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Percentage of Administered Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dog 2 mg/kg</td>
</tr>
<tr>
<td>Total radioactivity</td>
<td>78.2 (100.0)</td>
</tr>
<tr>
<td>Fasiglifam</td>
<td>10.8 (13.8)</td>
</tr>
<tr>
<td>M-I</td>
<td>&lt;LOQ (0.0)</td>
</tr>
<tr>
<td>Fasiglifam-G</td>
<td>39.4 (50.4)</td>
</tr>
<tr>
<td>Fasiglifam-Tau</td>
<td>4.5 (5.8)</td>
</tr>
<tr>
<td>Others</td>
<td>23.5 (30.0)</td>
</tr>
</tbody>
</table>

<LOQ, below the lower limit of quantitation; M-I, 7,6’-dimethyl-4’-[3-(methylsulfonyl)propoxy]-biphenyl-3-carboxylic acid.

**TABLE 3**

Uptake of \([^{14}C]\)fasiglifam and \([^{3}H]\)pravastatin into rat and dog hepatocytes and the inhibitory effect of cyclosporin A

<table>
<thead>
<tr>
<th>Compound</th>
<th>Concentration</th>
<th>Uptake Clearance (μl/min per milligram protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Rat (μl/min per milligram protein) Dog (μl/min per milligram protein)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rx704</td>
</tr>
<tr>
<td>Pravastatin</td>
<td>0.3</td>
<td>15.8</td>
</tr>
<tr>
<td>Pravastatin + CyA</td>
<td>0.3 + 10</td>
<td>2.8</td>
</tr>
<tr>
<td>Fasiglifam</td>
<td>0.3</td>
<td>689.6</td>
</tr>
<tr>
<td>Fasiglifam + CyA</td>
<td>0.3 + 10</td>
<td>632.8</td>
</tr>
</tbody>
</table>

CyA, cyclosporin A.
Concentrations of Fasiglifam and Fasiglifam-G in the Bile. The concentrations of fasiglifam and its metabolites in the pooled rat and dog bile over 24 hours after a single intraduodenal or oral dose of 2 or 200 mg/kg were determined. Within the same dose group, the concentrations of fasiglifam and fasiglifam-G in the dog bile were 5- to 10-fold higher than those in the rat bile (Table 5). The concentrations of 2'-6'-dimethyl-4'-[3-(methylsulfonyl)propoxy]biphenyl-3-carboxylic acid and fasiglifam-tau in dog bile were similar or lower than those in rat bile. The concentrations of fasiglifam and fasiglifam-G in dog bile were also determined after 14 days of repeated dosing of [14C]fasiglifam at 200 mg/kg per day. Following repeated dosing, the average concentrations of fasiglifam and fasiglifam-G in dog bile at 2 and 8 hours postdose ranged from 5280 to 11,087 μg/ml (individual values in four dogs ranged from 3509 to 12,956 μg/ml) (Table 6). Note that since the measurements in Table 5 are concentrations over 24 hours, the values in Table 5 cannot be compared with the individual time measurements in Table 6. No precipitate/crystalline material was observed in the bile collected from the gallbladder during the study. This study also indicated that the concentrations of fasiglifam and fasiglifam-G in the bile slightly increased (≤2-fold) with repeated dosing compared with those in dogs after a single oral dose of 200 mg/kg.

Determination of Bile Flow Rate and pH in Rats and Dogs in the Presence of [14C]Fasiglifam

Bile flow rates and pH values in rats and dogs were determined following a single intraduodenal (rats) or oral (dogs) administration of

---

Table 4

<table>
<thead>
<tr>
<th>Species</th>
<th>IC50 (μmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mrp2</td>
</tr>
<tr>
<td>Rat</td>
<td>—</td>
</tr>
<tr>
<td>Dog</td>
<td>—</td>
</tr>
</tbody>
</table>

—, not determined.

---
[14C]fasiglifam at 0, 2, or 200 mg/kg (where 0 mg/kg is the vehicle control). Data from the literature (Davies and Morris, 1993) and the present study indicate that the mean normal bile flow rate adjusted by body weight in dogs is about 4- to 8-fold slower than that in rats. At 2 mg/kg, the bile flow rates in rats and dogs were similar to those observed in the vehicle control groups (Table 7). At 200 mg/kg, the bile flow rates in rats and dogs were slightly higher than those observed in the vehicle control groups (Table 7). No significant change in the pH values of bile in rats and dogs was observed after a single intraduodenal (rats) and oral (dogs) dose of [14C]fasiglifam at 2 or 200 mg/kg (Table 7). However, following 14 days of repeated dosing at an oral dose of 200 mg/kg per day, the pH of the dog bile increased to a range of 6.8–7.6.

The In Vitro Solubility of Fasiglifam and Fasiglifam-G

The in vitro solubility of fasiglifam and fasiglifam-G in dog and human bile was determined using individual bile samples collected from the respective species spiked with different concentrations of [14C]fasiglifam or [14C]fasiglifam-G. Results of these studies showed that the solubility limit for both fasiglifam and fasiglifam-G was approximately 3000 µg/ml in dog bile and approximately 1000 µg/ml in human bile (Table 8). No apparent effect of either total bile acid concentrations or bile pH was noted on solubility.

Predicted Maximum Concentrations of Fasiglifam in Dog Bile

Using eq. 1, we would have predicted a maximum biliary concentration of 2590 µg/ml. This was calculated using the maximum plasma concentration of 315 µg/ml reported in Table 1, the total dog CL of fasiglifam of 29.8 ml/h per kilogram reported by Kogame et al. (2018), the extraction ratio of 0.138 determined in Table 2, and a bile flow rate of 0.5 ml/h per kilogram as given in Table 7, which is also the value reported by Davies and Morris (1993).

**Discussion**

Fasiglifam treatment in 4- to 39-week repeated-dose toxicity studies in dogs resulted in liver toxicity characterized by the elevation of aspartate aminotransferase, ALT, alkaline phosphatase, and/or bilirubin. Associated histopathological changes were characterized as portal/peripheral granulomatous inflammation with crystal formation. This toxicity was both dose and duration dependent. In the 39-week dog study, the liver toxicity observed at 150 mg/kg per day had either completely resolved or showed signs of recovery following a 13-week recovery period. The observed fasiglifam-related dog liver toxicity was characterized by conducting nonclinical mechanistic studies in vitro and in vivo. For comparison, mechanistic studies were also conducted in rats. In the repeated-dose toxicity studies in rats, the histopathological changes observed in dogs were not found in rats at doses up to 2000 mg/kg per day. For the in vivo mechanistic studies, oral doses of 2 and 200 mg/kg per day were used because 2 mg/kg per day was considered nontoxic (the human equivalent dose is approximately 67 mg/day based on body surface area), whereas doses of ≥150 mg/kg per day (the human equivalent dose for 150 mg/kg per day in dog is 5000 mg/day) resulted in liver toxicity after repeated dosing for ≥13 weeks in dogs. MALDI TOF MS analysis indicated that the crystalline material in the liver sections of affected dogs contained fasiglifam and fasiglifam-G, indicating that the dog liver toxicity could be characterized in terms of pharmacokinetics and physicochemistry of fasiglifam and its related compounds. No dog-specific metabolites were found in the plasma, liver, or bile; furthermore, no evidence of covalent binding of fasiglifam-G (an acyl glucuronide) to the plasma or liver proteins was noted in the dogs. Moreover, no significant accumulation of total radioactivity, fasiglifam, and/or fasiglifam-G was noted in the dog plasma or liver following 14 days of repeated oral dosing of [14C]fasiglifam at 200 mg/kg per day. Although the concentrations of fasiglifam in the rat liver were 2- to 10-fold higher than those in the dog liver at the same dose level (Fig. 2), no histopathological liver injury was observed in any rat toxicology studies, suggesting that fasiglifam is not directly toxic to hepatocytes.

Transporter studies showed that passive diffusion played a more important role than active transport in the hepatic uptake of fasiglifam in rats and dogs. No species difference was noted between rats and dogs in the CL of fasiglifam hepatic uptake and fasiglifam-G hepatobiliary efflux, or potential inhibition of hepatobiliary transporters by fasiglifam and fasiglifam-G. Therefore, the involvement of hepatic transporters could not solely account for the differences in the liver findings in the rat and dog toxicity studies.
Following a single intraduodenal or oral dose of \([^{14}C]\)fasiglifam at 2 or 200 mg/kg to rats and dogs, within the same dose group, the concentrations of total radioactivity, fasiglifam, and fasiglifam-G in dog bile were 5- to 10-fold higher than those in rat bile (Table 5), whereas their excretion (percentage of administered dose) was comparable between the two species (Table 2). The differences in concentrations are attributed to the difference in bile flow rate between the two species. In the vehicle group, the bile flow rate in dogs (12 to 13 ml/day per kilogram) was considerably slower than that in rats (44-49 ml/day per kilogram), which was consistent with published data (Davies and Morris, 1993). We note that the maximum plasma concentration reported here (Table 1) is consistent with that in the 39-week toxicity study in dogs, where a maximum concentration was 78 µg/ml for 40 mg/kg per day.

The bile concentration of fasiglifam was 7269 µg/ml at 8 hours after 14 days of repeated dosing of \([^{14}C]\)fasiglifam at 200 mg/kg per day, as shown in Table 6. This value is just under three times the calculated maximum biliary concentration in dogs of 2590 µg/ml (using eq. 1). We attempted to predict the maximum bile concentration in dogs using eq. 1, to see if it would be possible to predict the maximum bile concentration in humans. Assuming that the extraction ratio is similar between dogs and humans (0.138), using the total human CL of fasiglifam of 14.6 ml/h per kilogram (Kogame et al., 2018), the maximum plasma concentration of 5.3 µg/ml observed in T2DM patients for a 50 mg multiple daily dose study (Leitke et al., 2012), and a human bile flow rate of 0.24 ml/h per kilogram (Davies and Morris, 1993), a maximum bile concentration of 44.5 µg/ml would be predicted. We suggest that the solubility limit would be 20-fold higher than the predicted fasiglifam concentration and that even if our calculations underpredict by one-third of the dog data, or even if the underprediction is 7-fold off in a worst-case scenario, we would not expect biliary concentrations of fasiglifam to exceed the solubility limit for this compound. The in vitro solubility limit of fasiglifam in dog bile was approximately 3000 µg/ml. However, no crystalline material was visually observed in the dog bile collected from the gallbladder at the end of the 14-day dosing period (data on file), possibly because it is difficult to find the microscopic nature of the crystals and/or the duration of the study was insufficient for crystal growth.

The \(C_{\text{max,bile}}\) of fasiglifam-G could not be estimated due to the low or undetectable levels of the metabolite in plasma. From Tables 2 and 5 it can be seen in both rats and dogs that the average fasiglifam-G bile concentrations over 24 hours range from 3.7- to 7.2-fold higher than the fasiglifam bile concentrations. The same pattern is observed for the dog concentrations at 2 and 8 hours in Table 6; however, the ratios are only 1.3-1.6 greater. If fasiglifam-G bile concentrations in humans follow the same relative pattern with fasiglifam as observed in rats and dogs, again we would not expect fasiglifam-G concentrations to exceed the solubility limits given in the previous human studies.

Histopathological examination of the liver from affected dogs in repeat-dose toxicity studies with fasiglifam showed that crystal formation occurred primarily in and around the portal triads of the dog liver, and granulomatous inflammation was a secondary reaction to the presence of crystals in these areas. Toxicity of this nature is dose dependent and explains the dose- and duration-dependent nature of the dog liver toxicity.

In addition, assuming linear pharmacokinetics, we predicted the maximum concentrations of fasiglifam and fasiglifam-G in dog bile at the no observable adverse effect level (NOAEL) of 40 mg/kg per day. The predicted bile concentrations of these compounds at the NOAEL in the dog study did not exceed the solubility limit in the dog bile, indicating that crystal formation might not occur in the biliary tree of dogs at the NOAEL.

As shown previously, the predicted concentration in human bile indicated that the risk of crystal formation in human bile was minimal at the maximum recommended human dose (50 mg). The safety margin based on the ratio of the dog area under the plasma versus time-concentration curve at the NOAEL (854,000 ng h/ml at 40 mg/kg) (Wolenski et al., 2017) to the human area under the plasma versus time-concentration curve at the clinically efficacious dose (61,463.4 ng h/ml at 50 mg) (Mayer et al., 2014) was estimated to be more than 10-fold. However, the fasiglifam clinical development program was terminated owing to liver safety concerns. These facts indicate that the mechanism of liver toxicity might be different between humans and dogs. Although the fundamental pathogenesis of fasiglifam-induced liver injury in humans is still not well understood, nonclinical in vivo and in vitro studies have proposed theories for the pathogenesis caused by a fasiglifam-specific factor (Li et al., 2015; Wolenski et al., 2017), in which the inhibitory effect of fasiglifam on several hepatobiliary transporters might provide a possible mechanism of fasiglifam-induced liver injury in human. Hepatobiliary transporters are known to play an important role in bile acid homeostasis (Köck and Brouwer, 2012; Chiang, 2013). Therefore, the inhibition of the transporters is considered to lead to abnormal intracellular concentration of bile acid, and subsequently liver injury since bile acids have a detergent-like property (Pauli-Magnus et al., 2005; Marion et al., 2007). However, in many cases, drug-induced liver injury cannot be predicted by nonclinical animal models (Chan and Benet, 2018), and since severe drug-induced liver injury has a very low incidence (see http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf) (Björnsson et al., 2013; Fontana, 2014), in addition to drug-specific risk factors, patient-specific risk factors such as age, genetic polymorphisms, alcohol consumption, and/or medical history might also contribute to the susceptibility of drug-induced liver injury. Unfortunately, the patient-specific risk factors in fasiglifam clinical studies are not available.

In summary, high concentrations of fasiglifam and fasiglifam-G that exceeded the solubility limits of these compounds in dog bile were most likely the main causes of dog liver toxicity observed in repeat-dose toxicity studies. The formation of crystals and toxicity development require high biliary concentrations and sufficient study duration. The present study showed the importance of pharmacokinetic studies in drug development in terms of clarifying the mechanism of toxicity and safety.

### Table 8

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Dog (n = 8)</th>
<th>Human (n = 9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>([^{14}C])Fasiglifam</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recovery at 1000 µg/ml (%)</td>
<td>91.6-96.7</td>
<td>92.9-99.9</td>
</tr>
<tr>
<td>Recovery at 3000 µg/ml (%)</td>
<td>80.5-90.6</td>
<td>63.9-96.4</td>
</tr>
<tr>
<td>Recovery at 10,000 µg/ml (%)</td>
<td>63.3-77.5</td>
<td>20.6-78.1</td>
</tr>
<tr>
<td>pH</td>
<td>6.8-7.8</td>
<td>6.4-7.6</td>
</tr>
<tr>
<td>Total bile acid concentration (mmol/l)</td>
<td>119-187</td>
<td>11.6-139</td>
</tr>
</tbody>
</table>

*Recovery of the spiked radioactive material.

TABLE 8

The in vitro solubility of \([^{14}C]\)fasiglifam and \([^{14}C]\)fasiglifam-G, pH, and total bile acid concentrations in dog bile

Values represent the range for eight dogs and nine humans.
assessment, although the mechanism of fasiglifam-related liver toxicity in clinical studies is still unclear.

**Authorship Contributions**

**Participated in research design:** Kogame, Moriya, Pan, Fukui, Tagawa, Benet.

**Conducted experiments:** Kogame, Moriya, Mori, Ebihara.

**Performed data analysis:** Kogame, Moriya, Mori, Ebihara, Fukui, Tagawa.

**Wrote or contributed to the writing of the manuscript:** Kogame, Moriya, Mori, Pan, Morohashi, Ebihara, Fukui, Tagawa, Benet.

**References**


**Address correspondence to:** Akifumi Kogame, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan. E-mail: akifumi.kogame@takeda.com